ExploreCOVID – identification of optimal CT imaging biomarkers in combination with clinical markers and RT-PCR for diagnosis of COVID-19

ExploreCOVID – identification of optimal CT imaging biomarkers in combination with clinical markers and RT-PCR for diagnosis of COVID-19 - ExploreCOVID

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00023913

Enrollment

1000

Registered

2020-12-21

Start date

2020-12-22

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1

Interventions

Group 1: Assessment of the existing chest CT and collection of clinical data in the course -Patients with confirmed COVID-19 infection (PCR test positive) Group 2: - Patients with suspected COVID-19 a

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Study population: • Patients with confirmed COVID-19 infection • Patients with suspected COVID-19 associated respiratory syndrome with negative PCR testing • Existing CT images of the chest • Age = 18 years Control cohort: Healthy patients without symptoms and patients with lung diseases without suspicion of COVID-19

Exclusion criteria

Exclusion criteria: Age < 18 years

Design outcomes

Primary

Measure	Time frame
1. Detection of imaging biomarkers for data-based diagnosis and treatment of COVID-19 patients	—

Secondary

Measure	Time frame
2. Correlation of radiological findings with RT-PCR, clinical biomarkers and the course of the COVID-19 disease 3. Development of a clinical guideline and definition of clinically relevant imaging biomarkers for diagnosis, risk stratification and treatment response of COVID-19 patients 4. Development of an evidence-based guideline for the stratification and use of high-risk patients with the provision of an open access database.	—

Measure

Time frame

2. Correlation of radiological findings with RT-PCR, clinical biomarkers and the course of the COVID-19 disease 3. Development of a clinical guideline and definition of clinically relevant imaging biomarkers for diagnosis, risk stratification and treatment response of COVID-19 patients 4. Development of an evidence-based guideline for the stratification and use of high-risk patients with the provision of an open access database.

—

Countries

Germany

Contacts

Public ContactPascal Probst

Klinik für Allgemein-, Viszeral- und Transplantationschirurgie

pascal.probst@med.uni-heidelberg.de06221-5636209

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026